In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Intravenous milrinone for symptomatic cerebral vasospasm: A single center case-control study

    Final Number:
    1352

    Authors:
    Karim Elayoubi MD; Adil Harroud; Michel W. Bojanowski MD, FRCS(C); Jean Raymond

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Cerebral vasospasm (CV) remains a serious cause of morbidity and mortality following subarachnoid hemorrhage. Milrinone, a type III phosphodiesterase inhibitor with positive inotropic and vasodilatory properties, has been increasingly used in the treatment of CV. However, data on its safety and clinical efficacy remains limited.

    Methods: We performed a retrospective study on 93 consecutives patients with symptomatic cerebral vasospasm treated between 2000 and 2010: 60 received standard hyperdynamic therapy (SHT) and intravenous milrinone, whereas 33 received SHT without milrinone. The proportion of new onset CV-related infarcts on CT-scan, the clinical outcomes (mRS) at 3 months and 2 years and mortality were compared between the 2 groups. Logistic regression was used to study the relationship between Fisher, Hunt & Hess grade, radiological CV severity, CV-related infarct, the use of milrinone and clinical outcome.

    Results: Sixty patients received milrinone for an average of 6.1 ± 3.3 days (range : 1-16). There were no complications related to milrinone. A new-onset CV-related infarct occurred in 51.6 % of patients who received IV milrinone compared to 57.6 % of patients who did not received milrinone. A favorable clinical outcome (mRS= 2) was observed in 63.3% (n=38) of patients receiving milrinone compared to 57.6% (n=19) not treated with milrinone. No statistically significant differences were observed between patients treated with and without milrinone in terms of CV-related infarcts, mortality and functional outcome.

    Conclusions: Milrinone seems to be safe for the treatment of symptomatic CV, but no clear advantage as compared to SHT have been demonstrated in this retrospective study. A prospective randomized study is needed to evaluate its efficacy.

    Patient Care: As far as the knowledge of the authors, this is the first case control study comparing the following 2 groups of patients: one who received the standard treatment for symptomatic cerebral vasospasm, and the other who received the standard treatment associated with intravenous milrinone. This case control study represents a good data base to help the building of a clinical trial about intravenous milrinone as treatment of symptomatic cerebral vasospasm.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1. Describe the pathophysiology of cerebral vasospasm. 2. The morbidity and mortality associated with cerebral vasospasm. 3. The standard treatment of cerebral vasospasm. 4. Resume and critics the clinical trials about cerebral vasospasm.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy